Agios Pharmaceuticals, Inc.
AGIO
$25.72
-$1.99-7.18%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 10.73M | 8.96M | 8.62M | 8.19M | 7.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.73M | 8.96M | 8.62M | 8.19M | 7.10M |
| Cost of Revenue | 84.07M | 73.24M | 78.90M | 69.25M | 78.08M |
| Gross Profit | -73.34M | -64.27M | -70.28M | -61.06M | -70.97M |
| SG&A Expenses | 51.70M | 38.54M | 35.54M | 31.01M | 35.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 135.77M | 111.78M | 114.43M | 100.26M | 113.38M |
| Operating Income | -125.04M | -102.81M | -105.82M | -92.07M | -106.28M |
| Income Before Tax | -105.40M | 1.00B | -96.12M | -81.55M | -95.94M |
| Income Tax Expenses | -8.88M | 53.12M | -- | -- | -- |
| Earnings from Continuing Operations | -96.52M | 947.92M | -96.12M | -81.55M | -95.94M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -96.52M | 947.92M | -96.12M | -81.55M | -95.94M |
| EBIT | -125.04M | -102.81M | -105.82M | -92.07M | -106.28M |
| EBITDA | -123.67M | -101.47M | -104.22M | -90.72M | -104.87M |
| EPS Basic | -1.69 | 16.65 | -1.69 | -1.45 | -1.72 |
| Normalized Basic EPS | -1.15 | -0.97 | -1.06 | -0.90 | -1.07 |
| EPS Diluted | -1.69 | 16.22 | -1.69 | -1.45 | -1.72 |
| Normalized Diluted EPS | -1.15 | -0.94 | -1.06 | -0.90 | -1.07 |
| Average Basic Shares Outstanding | 57.10M | 56.94M | 56.80M | 56.38M | 55.93M |
| Average Diluted Shares Outstanding | 57.10M | 58.43M | 56.80M | 56.38M | 55.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
